Details

Autor(en) / Beteiligte

• Hoeper, Marius M
• Kramer, Tilmann
• Pan, Zixuan
• Eichstaedt, Christina A
• Spiesshoefer, Jens
• Benjamin, Nicola
• Olsson, Karen M
• Meyer, Katrin
• Vizza, Carmine Dario
• Vonk-Noordegraaf, Anton
• Distler, Oliver
• Opitz, Christian
• Gibbs, J Simon R
• Delcroix, Marion
• Ghofrani, H Ardeschir
• Huscher, Doerte
• Pittrow, David
• Rosenkranz, Stephan
• Grünig, Ekkehard

Titel

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model

Ist Teil von

• The European respiratory journal, 2017-08, Vol.50 (2), p.1700740-1700740

Ort / Verlag

England: European Respiratory Society Journals Ltd

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5-10% and >10%, respectively. This risk assessment strategy awaits validation.We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation.Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups.An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.